Skip to content

Addiction research published in 2021

Page 2 of 4: studies 21 to 40 of 61, newest first. Back to the addiction overview

Studies

Therapeutic potential of ketamine for alcohol use disorder.

Neuroscience & Biobehavioral Reviews July 1, 2021 Stephen D Worrell, Thomas J Gould 47 citations

Excessive alcohol consumption is involved in 1/10 of deaths of U.S. working-age adults and costs the country around $250,000,000 yearly. While Alcohol Use Disorder (AUD) pathology is complex and involves multiple neurotransmitter systems, changes in synaptic plasticity, hippocampal neurogenesis, and neural connectivity have been implicated in the behavioral characteristics of AUD. Depressed...

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?

Preprints.org June 28, 2021 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 1 citation preprint

Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s...

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Brain Sciences June 27, 2021 Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso et al. 114 citations

The obsessive-compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive-compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control...

DOI: 10.3390/brainsci11070856 (opens in new tab) Ketamine Eating disorders Obsessive compulsive Substance use +2

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders

Canadian Journal of Health Technologies June 24, 2021 Yi‐sheng Chao, Jennifer Horton 5 citations

Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...

Psychedelics and health behaviour change

Journal of Psychopharmacology May 29, 2021 Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann et al. 87 citations

Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed...

O Uso da ibogaína no manejo da dependência de drogas no Brasil

May 28, 2021 Bruno Ramos Gomes

This research qualitatively investigated four treatments for addiction currently in Brazi that use ibogaine as the main tool in the process.Ibogaine is a substance derived from an African plant, Tabernanthe iboga, traditionally used in its region of origin and which leads to intense changes in physical and psychic sensations, considered a psychedelic.Before entering the field, an integrative...

Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center

Frontiers in Pharmacology May 19, 2021 Brian Rush, Olivia Marcus, Sara Mallén García et al. 26 citations

The present study describes the protocol for the Ayahuasca Treatment Outcome Project (ATOP) with a special focus on the evaluation of addiction treatment services provided through Takiwasi Center, the first ATOP study site. The goal of the project is to assess treatment outcomes and understand the therapeutic mechanisms of an Ayahuasca-assisted, integrative treatment model for addiction...

DOI: 10.3389/fphar.2021.659644 (opens in new tab) Ayahuasca Context archaeology Protocol science Focus group +8

A Pilot Randomized Clinical Trial of Mindfulness-Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for People with Opioid Use Disorder and Chronic Pain: Impact on Illicit Drug Use, Health, and Well-Being

Journal of Substance Abuse Treatment May 8, 2021 Nina A Cooperman, Adam W. Hanley, Anna Kline et al.

Background: Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse. Mindfulness-Oriented Recovery Enhancement (MORE) is one of the few interventions developed and tested as an integrated treatment to simultaneously address both pain and illicit...

The Resilient Recovery from Substance Addiction: The Role of Self-transcendence Values and Hope

April 29, 2021 C. Russo, Daniela Barni, I. Zagrean et al.

Background: Substance addiction is a psychosocial problem facing many people today. While the previous trend in addiction treatment was the harm reduction approach, nowadays it is fully recognized the importance of promoting human resources in order to help people to face the rehabilitation process, to prevent the risk of treatment dropout and future relapses, and to positively re-integrate...

Mindful Positive Emotion Regulation as a Treatment for Addiction: From Hedonic Pleasure to Self-Transcendent Meaning.

Current Opinion in Behavioral Sciences April 24, 2021 Eric L Garland

Chronic drug use is theorized to induce cortico-striatal neuroplasticity, driving an allostatic process marked by increased sensitivity to drug-related cues and decreased sensitivity to natural rewards that results in anhedonia and a dearth of positive affect. As such, positive emotion regulation represents a key mechanistic target for addictions treatment. This paper provides a conceptual...

MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers

Trials April 23, 2021 Robin J Murphy, Rachael Sumner, William Evans et al. 23 citations

BACKGROUND: Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as "microdosing", has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional domains. Rigorously controlled studies to date, however, have been limited in scope and have failed to produce results comparable to those reported...

Ayahuasca potential benefits

European Psychiatry April 1, 2021 R. Pinilla, Carmen Rocamora Rodriguez, D. Batet-Sanchez et al. 3 citations

Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinical existing evidence. Methods A literature review was carried out in the databases pubmed, clinical key and texts of scientific dissemination. Results There´s scientific literature about the potential therapeutic use of ayahuasca in dependencies,...

Treating addiction with psychedelics - are we waking up?

European Psychiatry April 1, 2021 Jackelyne Gabrielle Jesus de Miranda, Mario Barbosa, I. Figueiredo et al.

Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both...

Psychedelics and psychiatric disorders: A emerging role

European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation

Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...

Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)

March 24, 2021 Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann et al. 1 citation preprint

Healthful behaviors such as maintaining a balanced diet, being physically active, and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases, and other serious conditions. The burden of the so-called “lifestyle diseases” - in personal suffering, premature mortality, and public health costs - is considerable. Consequently, interventions...

Minding the Gap: Leveraging Mindfulness to Inform Cue Exposure Treatment for Substance Use Disorders.

Frontiers in Psychology March 22, 2021

Despite extinction-based processes demonstrating efficacy in the animal extinction and human anxiety literatures, extinction for substance use disorders (SUD) has shown poor efficacy (i. e., cue exposure treatment [CET]). Reasons for this lack of success include common threats to extinction, such as renewal and reinstatement. In recent decades, research on mindfulness for SUD has flourished,...

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Australian & New Zealand Journal of Psychiatry March 21, 2021 Daniel Perkins, Jerome Sarris, Susan L. Rossell et al. 53 citations

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...

DOI: 10.1177/0004867421998785 (opens in new tab) Psilocybin Mental health Psychotherapist Hallucinogen

New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.

Journal of Food and Drug Analysis March 15, 2021 Wen-Jing Yu, Linda B. Cottler, Jih-Heng Li 13 citations

Use of New Psychoactive Substances (NPS) has posed a global threat to public health and the security of the population. As of December 2019, the NPS items identified in total have outnumbered by three to one the controlled substances listed in the 1961 and 1971 UN Drug Conventions. However, most of these NPS have not been scheduled by the United Nations because of their easy modification on the...

DOI: 10.38212/2224-6614.3225 (opens in new tab) Full text (opens in new tab) Addiction Psychoactive substances Traditional controlled drugs Drug misuse +11

Social Exclusion, Self-Forgiveness, Mindfulness, and Internet Addiction in College Students: a Moderated Mediation Approach.

International Journal of Mental Health and Addiction March 8, 2021 Gökmen Arslan, Muhammet Coşkun

Internet addiction is a growingly prevalent behavioral addiction that causes numerous psychosocial problems. Investigating the causes and consequences of Internet addiction is fundamental to comprehend and prevent it. Therefore, the current study provided protective and promotive factors for undesired effects of social exclusion on Internet addiction. The study examined a moderated mediation...

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Risk Management and Healthcare Policy March 1, 2021 Rafael G. Dos Santos, José Carlos Bouso, Juliana Mendes Rocha et al. 58 citations

Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT2A receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for...